Mumbai headquartered Sun Pharmaceutical Industries Limited, India's largest drugmaker, acquired Lexington, MA-based Concert Pharmaceuticals Inc., for $576 million in cash. Sun Pharma offered Concert $8 per share, representing a premium of 16% to the stock's last close. Concert's lead candidate, deuruxolitinib, is currently being evaluated in a late-stage study as...